Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)
Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)
Not yet recruiting · NCT07535489 · Registry updated 2026-04-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2) | Moderately to Severely Active Ulcerative Colitis (UC) | Not yet recruiting | Phase 2 | 2026-04-17 | NCT07535489 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanjing Immunophage Biotech Co., Ltd | 4 |
| Peking Union Medical College | 33 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking Union Medical College Hospital Chinese Academy of Medical Sciences | Beijing | China | 1 |